Table 1.
Demographic characteristics of and risk factors for cardiovascular disease (CVD) in patients undergoing follow-up in the Data Collection on Adverse Events of Anti-HIV Drugs Study in the 6 calendar periods.
| Calendar period |
||||||
|---|---|---|---|---|---|---|
| Variable | 1999–2000 | 2001 | 2002 | 2003 | 2004 | 2005–2006 |
| No. of patients who underwent follow-up | 21,483 | 23,705 | 26,613 | 28,400 | 28,495 | 25,613 |
| Male sex | 16,203 (75.4) | 17,922 (75.6) | 19,906 (74.8) | 21,092 (74.3) | 21,027 (73.8) | 18,857 (73.6) |
| Age, median years (IQR) | 39 (35–45) | 40 (35–46) | 40 (36–47) | 41 (36–48) | 42 (37–48) | 43 (38–49) |
| Risk group | ||||||
| Men who have sex with men | 9487 (44.2) | 10,638 (44.9) | 11,841 (44.5) | 12,554 (44.2) | 12,472 (43.8) | 11,244 (43.9) |
| Injection drug user | 4526 (21.1) | 4673 (19.7) | 4765 (17.9) | 4779 (16.8) | 4656 (16.3) | 4135 (16.1) |
| Heterosexual | 5769 (26.9) | 6277 (26.5) | 7602 (28.6) | 8450 (29.8) | 8808 (30.9) | 7903 (30.9) |
| Other or unknown | 1701 (7.9) | 2117 (8.9) | 2405 (9.0) | 2617 (9.2) | 2559 (9.0) | 2331 (9.1) |
| Ethnicity | ||||||
| White | 10,615 (49.4) | 11,260 (47.5) | 11,703 (44.0) | 12,130 (42.7) | 12,544 (44.0) | 11,170 (43.6) |
| Black African | 2027 (9.4) | 2451 (10.3) | 2632 (9.9) | 2761 (9.7) | 2794 (9.8) | 2494 (9.7) |
| Other | 610 (2.8) | 751 (3.2) | 766 (2.9) | 790 (2.8) | 847 (3.0) | 770 (3.0) |
| Not known | 8231 (38.3) | 9243 (39.0) | 11,512 (43.3) | 12,719 (44.8) | 12,310 (43.2) | 11,179 (43.7) |
| Risk factor for CVD | ||||||
| Older agea | 5375 (25.0) | 6515 (27.5) | 7672 (28.8) | 8817 (31.1) | 9520 (33.4) | 9529 (37.2) |
| Current smokerb | 8508 (47.5) | 9307 (47.7) | 9419 (44.5) | 8772 (39.5) | 8800 (38.7) | 7868 (38.4) |
| Previous CVD | 418 (2.0) | 543 (2.3) | 648 (2.4) | 749 (2.6) | 825 (2.9) | 814 (3.2) |
| Diabetes mellitus | 807 (3.8) | 1005 (4.2) | 1180 (4.4) | 1376 (4.9) | 1406 (4.9) | 1321 (5.2) |
| Family history of CVD | 1525 (7.1) | 1732 (7.3) | 1983 (7.5) | 2082 (7.3) | 2225 (7.8) | 2142 (8.4) |
| Hypertension | 2237 (10.4) | 2881 (12.2) | 3479 (13.1) | 4091 (14.4) | 4853 (17.0) | 4792 (18.7) |
| Received lipid-lowering therapyc | 1235 (6.3) | 1885 (8.9) | 2399 (10.0) | 2918 (11.3) | 3395 (13.0) | 3527 (15.1) |
| Dyslipidaemia | 7363 (34.3) | 8678 (36.6) | 9344 (35.1) | 10,006 (35.2) | 10,353 (36.3) | 9098 (35.5) |
| Underwent an invasive procedure for CVDd | ||||||
| Prior to myocardial infarction or stroke | 79 (0.4) | 96 (0.4) | 116 (0.4) | 139 (0.5) | 158 (0.6) | 157 (0.6) |
| After myocardial infarction or stroke | 85 (0.4) | 128 (0.5) | 163 (0.6) | 208 (0.7) | 249 (0.9) | 256 (1.0) |
| High-risk individuale | 7576 (35.3) | 9045 (38.2) | 9896 (37.2) | 10,483 (36.9) | 11,206 (39.3) | 10,569 (41.3) |
NOTE. Data are no. (%) of patients, unless otherwise indicated. All comparisons were statistically significant (P<.001).
Men aged ⩾45 years and women aged ⩾55 years were considered to be of older age.
Based on those individuals for whom this information was available (17,931 in 1999–2000, 19,529 in 2001, 21,180 in 2002, 22,224 in 2003, 22,766 in 2004, and 20,479 in 2005–2006).
Based on information from 10 of the 11 cohorts.
Invasive procedures (coronary artery bypass, carotic endarterectomy, or angioplasty/stenting) were considered to be prior to myocardial infarction or stroke if they occurred in individuals who did not experience a myocardial infarction or stroke or in those who experienced one of these events, if the procedure occurred at least 1 month prior to the event.
High-risk individuals were those who had previous CVD, had received a diagnosis of diabetes mellitus, or had ⩾2 risk factors for CVD (see Methods).